Annual report pursuant to Section 13 and 15(d)

SUBSEQUENT EVENT (Details)

v3.10.0.1
SUBSEQUENT EVENT (Details) - Grifols - Subsequent events - Commercialization license agreement
$ in Millions
1 Months Ended
Jan. 31, 2019
USD ($)
Subsequent Event [Line Items]  
Upfront payment received $ 30.0
Contingent acquisition one-time agreement termination payment $ 60.0
Prior written notice following the second anniversary of the first MAA approval of fostamatinib in Europe and Turkey  
Subsequent Event [Line Items]  
Notice period for termination of agreement 18 months
Right to terminate agreement within number of months after second anniversary 6 months
Terminated agreement upon prior written notice within six months after second anniversary of agreement  
Subsequent Event [Line Items]  
Notice period for termination of agreement 60 days
Contingent upfront fee, refund requirement $ 25.0
Maximum | fostamatinib  
Subsequent Event [Line Items]  
Royalty payment as a percentage of net sales 30.00%
Commercial Milestones  
Subsequent Event [Line Items]  
Contingent payments $ 297.5
EMA approval of fostamatinib for treatment of chronic ITP | fostamatinib  
Subsequent Event [Line Items]  
Contingent payments 17.5
EMA approval of fostamatinib | fostamatinib  
Subsequent Event [Line Items]  
Contingent payments $ 2.5